| 67.78 -1.53 (-2.21%) | 02-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 87.96 | 1-year : | 98.76 |
| Resists | First : | 75.31 | Second : | 84.55 |
| Pivot price | 66.85  |
|||
| Supports | First : | 60.34 | Second : | 50.21 |
| MAs | MA(5) : | 66.1  |
MA(20) : | 69.87 |
| MA(100) : | 64.46 |
MA(250) : | 48.43 |
|
| MACD | MACD : | -2.6 |
Signal : | -2.6 |
| %K %D | K(14,3) : | 43.6 |
D(3) : | 31.8 |
| RSI | RSI(14): 45.5 |
|||
| 52-week | High : | 84.55 | Low : | 26.2 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ APGE ] has closed below upper band by 42.8%. Bollinger Bands are 0% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 71.22 - 71.58 | 71.58 - 71.86 |
| Low: | 65.98 - 66.34 | 66.34 - 66.63 |
| Close: | 67.2 - 67.81 | 67.81 - 68.29 |
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
Fri, 13 Feb 2026
Michael Thomas Henderson Sells 20,000 Shares of Apogee Therapeutics (NASDAQ:APGE) Stock - MarketBeat
Thu, 12 Feb 2026
APGE: Quarterly dosing, rapid itch relief, and strong safety set up a 2029 launch to challenge market leaders - TradingView
Thu, 12 Feb 2026
Candriam S.C.A. Invests $5.01 Million in Apogee Therapeutics Inc. $APGE - MarketBeat
Thu, 05 Feb 2026
Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewswire
Wed, 28 Jan 2026
Exane Asset Management Invests $2.05 Million in Apogee Therapeutics Inc. $APGE - MarketBeat
Thu, 22 Jan 2026
Fairmount Healthcare Fund II L.P. sells Apogee (APGE) shares for $133.53 million - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 55 (M) |
| Shares Float | 50 (M) |
| Held by Insiders | 6.1 (%) |
| Held by Institutions | 112.7 (%) |
| Shares Short | 8,090 (K) |
| Shares Short P.Month | 8,470 (K) |
| EPS | -4.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.89 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -25.3 % |
| Return on Equity (ttm) | -38.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -5.15 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -232 (M) |
| Levered Free Cash Flow | -143 (M) |
| PE Ratio | -16.54 |
| PEG Ratio | 0 |
| Price to Book value | 6.85 |
| Price to Sales | 0 |
| Price to Cash Flow | -15.99 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|